Emerging Company Profile: US firm Peptilogics is advancing through the clinic with its lead orthopedic anti-infective drug candidate based on an AI platform that utilizes algorithms to improve peptide design.
Peptilogics, Inc. is planning a 2026 US filing of its lead asset in an orphan orthopedic indication as it works to validate its AI platform that can design peptides with enhanced risk-benefit profiles regardless of drug target or class.
CEO Jonathan Steckbeck told Scrip his rationale for founding the Pittsburgh, PA-based firm in 2013 was two-fold. “The first reason...
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Emerging Company Profile: Backed by Flagship Pioneering, Empress deploys its Chemilogics platform to seek leads for small molecule therapies in inflammation, immunology, cancer and metabolic disease.
Emerging Company Profile: Efficacy data on the young group’s first pH-engineered antibody-drug conjugate could come next year, and potential partners will be watching.
Emerging Company Profile: The eight-year-old vaccine firm is planning clinical trials in the Philippines and Brazil to see how its synthetic viral peptide vaccine technology stands up against coronaviruses and dengue fever.
The start-up launched last year with Phase III-ready upacicalcet, which has nearly completed two pivotal trials in secondary hyperparathyroidism and for which it has exclusive rights outside of Asia.
Emerging Company Profile: Backed by Flagship Pioneering, Empress deploys its Chemilogics platform to seek leads for small molecule therapies in inflammation, immunology, cancer and metabolic disease.
Discontinuation of the AML study created concern about potential readthrough to a pivotal MDS trial, but the company and analysts pointed out differences in the diseases.
